TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25789456

Group type: EXPERIMENTAL
Intervention: Heat health warning (HHW) and water delivery (HHW+W)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Heat health warning (HHW)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Household water delivery (part of HHW+W)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1072
Study: 23921361

Group type: EXPERIMENTAL
Intervention: Immediate treatment with intrauterine insemination (IUI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 99
Study: 21161715

Group type: EXPERIMENTAL
Intervention: BOTOX®
Number of subjects: 65

Group type: COMPARATOR
Intervention: Xeomin®
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: BOTOX® and Xeomin®
Number of subjects: 65
Study: 19213976

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release (12.5 mg-50 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 17694662

Group type: EXPERIMENTAL
Intervention: Maintaining normal body temperature with water market and forced air heater
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monitoring body temperature without treatment
Number of subjects: 50
Study: 15238968

Group type: EXPERIMENTAL
Intervention: Outreach clinic consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Main base clinic consultations
Number of subjects: 0
Study: 12478881

Group type: EXPERIMENTAL
Intervention: Ketoconazole (up to 800 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9809930

Group type: EXPERIMENTAL
Intervention: Calcium antagonist-based strategy (verapamil)
Number of subjects: 27000

Group type: COMPARATOR
Intervention: Beta-blocker/diuretic-based strategy (atenolol/hydrochlorothiazide)
Number of subjects: 27000
Study: 7659626

Group type: EXPERIMENTAL
Intervention: Mailed health education booklet
Number of subjects: 3913

Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 3913
Study: 2576365

Group type: EXPERIMENTAL
Intervention: picumast dihydrochloride 1 mg twice daily for 6 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: picumast dihydrochloride
Number of subjects: 107
Study: 8748

Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: D-propranolol
Number of subjects: 54
Study: 30523908

Group type: EXPERIMENTAL
Intervention: Zinc-lactate-containing mouthwash (10 ml/30 s)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zinc-lactate-containing mouthwash (15 ml/60 s)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rinse without zinc-lactate (3 droplets/10 ml tap water/30 s)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tap water (10 ml/30 s)
Number of subjects: 16
Study: 29176548

Group type: EXPERIMENTAL
Intervention: Logistic staff determining replenishment needs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nursing staff determining replenishment needs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nursing staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of outstanding orders between groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative risk of outstanding orders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of cases required for an outstanding order
Number of subjects: 0
Study: 25351498

Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg daily in tapering doses)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 192
Study: 23804278

Group type: EXPERIMENTAL
Intervention: Oral clopidogrel (CLO) 75 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-dose aspirin (ASA) 81 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control site for NO-dependent vasodilation
Number of subjects: 9
Study: 20938374

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: Podophyllotoxin 0.5% solution
Number of subjects: 45
Study: 19910376

Group type: EXPERIMENTAL
Intervention: Tamoxifen for breast cancer prevention
Number of subjects: 815
Study: 16802350

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 12723101

Group type: EXPERIMENTAL
Intervention: Colgate Motion Toothbrush
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral-B CrossAction Toothbrush
Number of subjects: 126
Study: 11137927

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Oral anticoagulants (OAs)
Number of subjects: 158
Study: 9869369

Group type: EXPERIMENTAL
Intervention: Pilocarpine (P) administered by the ocular route
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8018980

Group type: EXPERIMENTAL
Intervention: nizatidine
Number of subjects: 241

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study: 2589233

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 24 mg in 5 doses
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 1 mg/kg as a single dose
Number of subjects: 25
Study: 782470

Group type: EXPERIMENTAL
Intervention: Pramiverine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31062692

Group type: EXPERIMENTAL
Intervention: Absorb
Number of subjects: 1845

Group type: COMPARATOR
Intervention: XIENCE
Number of subjects: 1845
Study: 30573277

Group type: EXPERIMENTAL
Intervention: Olaratumab + mitoxantrone/prednisone
Number of subjects: 123

Group type: COMPARATOR
Intervention: Mitoxantrone/prednisone
Number of subjects: 123
Study: 29944516

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous methylprednisolone 125 mg (group MP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Isotonic saline intravenous (group C)
Number of subjects: 134
Study: 27522037

Group type: EXPERIMENTAL
Intervention: Bitter tastant mixture (0.88 mg SOA, 0.088 mg QE, 0.22 mg RF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (non-bitter)
Number of subjects: 60
Study: 25175079

Group type: EXPERIMENTAL
Intervention: Supraomohyoid neck dissection (SOND)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Modified radical neck dissection (MRND)
Number of subjects: 322
Study: 22820896

Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dalcetrapib alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat (various doses)
Number of subjects: 24
Study: 21070458

Group type: EXPERIMENTAL
Intervention: LED photomodulation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 33
Study: 17692727

Group type: EXPERIMENTAL
Intervention: RNF (Rebif® New Formulation, 44 μg/0.5 mL SC tiw)
Number of subjects: 260

Group type: COMPARATOR
Intervention: EVIDENCE study (approved formulation of IFN‐β1a, identical regimen)
Number of subjects: 260
Study: 16332661

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (12 mg Fe/d for 6 d/wk for 35 wk)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Electrolytic iron (12 mg Fe/d for 6 d/wk for 35 wk)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Hydrogen-reduced iron (12 mg Fe/d for 6 d/wk for 35 wk)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no fortification)
Number of subjects: 330
Study: 11824947

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Infliximab (both dosages)
Number of subjects: 6
Study: 9915379

Group type: EXPERIMENTAL
Intervention: Neoprene lumbar brace
Number of subjects: 40
Study: 7770734

Group type: EXPERIMENTAL
Intervention: Intensive Psychiatric Community Care (IPCC)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Standard VA care
Number of subjects: 873
Study: 2279212

Group type: EXPERIMENTAL
Intervention: methohexitone
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 383171

Group type: EXPERIMENTAL
Intervention: radio-chemotherapy combined with the methanol extraction residue of BCG (MER)
Number of subjects: 53

Group type: COMPARATOR
Intervention: radio-chemotherapy
Number of subjects: 53
Study: 31698920

Group type: EXPERIMENTAL
Intervention: Button-activated ENDS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Other ENDS device
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both ENDS devices
Number of subjects: 17
Study: 31136817

Group type: EXPERIMENTAL
Intervention: Embrace™ WetBond™ (moisture tolerant resin sealant)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fuji TRIAGE® (glass ionomer sealant)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DIAGNOdent readings
Number of subjects: 40
Study: 27279368

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 25998755

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (HSM)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Conventional moxibustion
Number of subjects: 432

Group type: COMPARATOR
Intervention: Conventional injection with sodium hyaluronate
Number of subjects: 432
Study: 24414739

Group type: EXPERIMENTAL
Intervention: High FeNO group (≥80 ppb)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Moderate FeNO group (40-79 ppb)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low FeNO group (<40 ppb)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Normal-to-low FeNO group (<40 ppb)
Number of subjects: 93
Study: 22939848

Group type: EXPERIMENTAL
Intervention: Central Position (CE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right Visual Half-Field (RVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left Visual Half-Field (LVF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study: 19542104

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 microg kg(‐1) 90 s before propofol injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.1% premixed with propofol 3 mg kg(‐1) over 15 s
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of alfentanil and lidocaine
Number of subjects: 120
Study: 17043847

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 112

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (VDD)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin D
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: I-PTH and ALP levels
Number of subjects: 112
Study: 15241912

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength dentifrice containing 5% potassium nitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Market leader dentifrice containing 5% potassium nitrate
Number of subjects: 0
Study: 12114412

Group type: EXPERIMENTAL
Intervention: Bryostatin 1 (50 microg/m(2)) administered as a 24‐h continuous infusion on days 1 and 11 before and after high-dose 1-beta-D-arabinofuranosylcytosine (HiDAC; 1.5 g/m(2) every 12 h x 4 on days 2 and 3, and 9 and 10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bryostatin 1 (50 microg/m(2)) with HiDAC
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bryostatin 1 (50 microg/m(2))
Number of subjects: 23
Study: 9690979

Group type: EXPERIMENTAL
Intervention: milnacipran 100 mg/day
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: milnacipran 200 mg/day
Number of subjects: 289

Group type: COMPARATOR
Intervention: fluoxetine 20 mg/day
Number of subjects: 289
Study: 10354909

Group type: EXPERIMENTAL
Intervention: Normalized Peak Pressure (NPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure Contact Ratio (PCR)
Number of subjects: 0
Study: 2031969

Group type: COMPARATOR
Intervention: Intensive consolidation chemotherapy (SIC)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant (auto-BMT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (allo-BMT)
Number of subjects: 106
Study: 6663042

Group type: EXPERIMENTAL
Intervention: Proficient esophageal speakers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonproficient esophageal speakers
Number of subjects: 24
Study: 30171041

Group type: EXPERIMENTAL
Intervention: Exercise 1×/week for 6 weeks during active treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise 1×/week for 6 weeks
Number of subjects: 25
Study: 31597550

Group type: EXPERIMENTAL
Intervention: Genetically predicted 1-SD log-transformed increase in Lp(a) concentrations
Number of subjects: 446696

Group type: COMPARATOR
Intervention: Total ischemic stroke
Number of subjects: 446696

Group type: COMPARATOR
Intervention: Cardioembolic stroke
Number of subjects: 446696
Study: 30295684

Group type: EXPERIMENTAL
Intervention: Group 1 (rTMS at point -40; 48; 35)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Group 2 (rTMS at point -46; 45; 38)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Group 3 (rTMS at point -38; 44; 26)
Number of subjects: 46
Study: 26508441

Group type: EXPERIMENTAL
Intervention: Hypertensive patients during the ANBP2 clinical trial
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Hypertensive patients during post-trial follow-up
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Overall hypertensive patients
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Elderly hypertensive patients with various characteristics
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Elderly hypertensive patients with diabetes and smoking
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Elderly hypertensive patients with higher systolic blood pressure
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Elderly hypertensive patients diagnosed with HF
Number of subjects: 6083
Study: 24729398

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg from weeks 0 to 48
Number of subjects: 213

Group type: COMPARATOR
Intervention: placebo from weeks 0 to 20 followed by golimumab 50 mg from weeks 24 to 48
Number of subjects: 213
Study: 22581157

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: General psychiatric management
Number of subjects: 0
Study: 20858280

Group type: EXPERIMENTAL
Intervention: Albendazole (anthelmintic treatment)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 19378443

Group type: EXPERIMENTAL
Intervention: Self-help intervention with five communication sheets
Number of subjects: 1201
Study: 16819768

Group type: EXPERIMENTAL
Intervention: verapamil 2.5 mg and molsidomine 1 mg
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: verapamil 2.5 mg
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: verapamil 5 mg
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: molsidomine 1 mg
Number of subjects: 1219

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1219
Study: 12814763

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (500 mg of elemental calcium as carbonate and 400 IU of vitamin D bid for 12 months)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 192
Study: 10658002

Group type: EXPERIMENTAL
Intervention: Essential amino acids and carbohydrate drink (6 g essential amino acids, 35 g sucrose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Flavored placebo drink
Number of subjects: 6
Study: 9298338

Group type: EXPERIMENTAL
Intervention: EMG at tender points along the palpated myofascial band
Number of subjects: 164

Group type: COMPARATOR
Intervention: EMG at a nonselected site
Number of subjects: 164
Study: 8138866

Group type: EXPERIMENTAL
Intervention: Blind, placebo‐controlled medication trial (MT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Typical clinical procedures (TCP) evaluation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both MT and TCP conditions
Number of subjects: 24
Study: 2875674

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 30579511

Group type: EXPERIMENTAL
Intervention: Combined transoral sialolitectomy (CTS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open submaxillectomy
Number of subjects: 22
Study: 29523719

Group type: EXPERIMENTAL
Intervention: Medium-high STI risk perception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New sexual partners in the last 6 months (≥3 partners)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lack of condom use among women with a new partner in the last 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genital warts in the last year, binge drinking, and being single
Number of subjects: 0
Study: 26649604

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral cochlear implantation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unilateral cochlear implantation
Number of subjects: 38
Study: 24464258

Group type: COMPARATOR
Intervention: PAIR without albendazole (Group 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PAIR with albendazole 1 week before and 1 month after (Group 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PAIR with albendazole 1 week before and 3 months after (Group 3)
Number of subjects: 39
Study: 22370767

Group type: EXPERIMENTAL
Intervention: Prostate cancer surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective coronary artery stenting
Number of subjects: 0
Study: 19716319

Group type: EXPERIMENTAL
Intervention: Epalrestat 150 mg/day (EP group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 38
Study: 17925428

Group type: EXPERIMENTAL
Intervention: Protocol group (group A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 135
Study: 15808118

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 microg/day for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/day orally for 4 weeks
Number of subjects: 22
Study: 11950766

Group type: EXPERIMENTAL
Intervention: Monozygotic twins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control sample
Number of subjects: 0
Study: 8173242

Group type: EXPERIMENTAL
Intervention: VDT work (less than 6 hours daily)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: VDT work (more than 6 hours daily)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: VDT workers
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Monocular VDT workers (n = 3)
Number of subjects: 102
Study: 3555513

Group type: EXPERIMENTAL
Intervention: Bardac-22 (didecyl-dimethyl-ammonium chloride) in combination with prednicarbate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31544524

Group type: EXPERIMENTAL
Intervention: Abductor muscle strengthening rehabilitation program (extra 2-week rehabilitation after standard early postoperative rehabilitation)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard early postoperative rehabilitation
Number of subjects: 103
Study: 30820772

Group type: EXPERIMENTAL
Intervention: Resistance training plus photobiomodulation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resistance training plus placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no training or photobiomodulation)
Number of subjects: 45
Study: 27573881

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL) implantation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-toric intraocular lens (IOL) implantation
Number of subjects: 17
Study: 23702221

Group type: EXPERIMENTAL
Intervention: Novel, small-group sexual assault resistance education program (4 units, 12 hours total)
Number of subjects: 1716

Group type: COMPARATOR
Intervention: Current university practice of providing informational brochures
Number of subjects: 1716
Study: 21935847

Group type: EXPERIMENTAL
Intervention: Abductor Pollicis Longus (APL) tendon technique
Number of subjects: 53

Group type: COMPARATOR
Intervention: Flexor Carpi Radialis (FCR) tendon technique
Number of subjects: 53
Study: 19687490

Group type: EXPERIMENTAL
Intervention: TwHF extract, 60 mg 3 times daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: sulfasalazine, 1 g twice daily
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TwHF extract
Number of subjects: 121

Group type: COMPARATOR
Intervention: TwHF extract and sulfasalazine
Number of subjects: 121
Study: 16961789

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (migrainous children without FGIDs)
Number of subjects: 50
Study: 14968053

Group type: EXPERIMENTAL
Intervention: Teenage pregnancy and delivery
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (300 women aged more than 18 years)
Number of subjects: 276
Study: 11527646

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training for 8 weeks
Number of subjects: 16
Study: 9250803

Group type: EXPERIMENTAL
Intervention: PCR analyses for HHV‐8 detection
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Samples containing the EBV genome
Number of subjects: 19
Study: 8325046

Group type: EXPERIMENTAL
Intervention: 100 mg/day of oral sulodexide (enteric-coated tablets)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg/day of oral sulodexide (enteric-coated tablets)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Repeated administration of sulodexide (100 mg/day and 200 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sulodexide (oral administration)
Number of subjects: 16